NCT01596400CompletedPhase 1
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)
Kyowa Kirin Pharmaceutical Development Ltd12 sites in 1 country19 target enrollmentStarted: May 2012Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 19
- Locations
- 12
- Primary Endpoint
- Plasma concentration
Study Overview
Brief Summary
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 13 Years to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •13 to 17 years of age inclusive at screening.
- •Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate.
- •Written patient assent (as appropriate).
- •Confirmed malignancy.
- •Scheduled to receive 2 or more cycles* of emetogenic chemotherapy requiring 5-HT3 antagonist treatment.
- •Scheduled to receive one or more consecutive days of 5-HT3 antagonist treatment, per cycle, as CINV prophylaxis.
- •The cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment.
Exclusion Criteria
- •Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
- •Clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the Investigator's judgment may interfere with the study assessment or completion of the study.
- •Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.
- •Patients scheduled to have routine surgery during the study duration.
- •Patients with a life expectancy of < 6 months.
- •Scarring or significant skin disease on both upper arms.
- •Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
- •Patients who are known or thought to be sexually active must use effective birth control.**
- •Administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.
- •Any conditions associated with non-compliance.
- •Effective birth control includes absolute abstinence, or double barrier birth control methods, i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.
Arms & Interventions
Sancuso Arm
Experimental
Intervention: granisetron transdermal system (Drug)
IV Granisetron Arm
Active Comparator
IV
Intervention: Granisetron IV (Drug)
Outcomes
Primary Outcomes
Plasma concentration
Time Frame: Up to 7 days
Analysis of the plasma concentration of Intravenous granisetron vs transdermal granisetron in pediatric patients receiving chemotherapy over two sequential cycles.
Secondary Outcomes
- Chang is Safety from baseline(Up to 7 days)
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Withdrawn
Phase 1
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 YearsChemotherapy Induced Nausea and VomitingNCT01596413Kyowa Kirin Pharmaceutical Development Ltd
Withdrawn
Phase 1
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 YearsChemotherapy Induced Nausea and VomitingNCT01596426Kyowa Kirin Pharmaceutical Development Ltd
Withdrawn
Phase 1
Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With AsthmaAsthmaNCT01395485Amgen
Completed
Phase 1
Pharmacokinetics in AdolescentsAsthmaNCT01196689AstraZeneca21
Completed
Phase 1
Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions22q11.2 Deletion SyndromeNCT02895906Aevi Genomic Medicine, LLC, a Cerecor company2